Medicus Pharma Ltd.

MDCX

NASDAQ

Healthcare

Biotechnology

W. Conshohocken, CA12 employeesmedicuspharma.com

$0.45

+0.03(6.2%)

52W $0.39 – $7.78

AI-generated from 10-K FY2025 filed Mar 24, 2026

Medicus Pharma Ltd.

$10MMkt Cap

—Rev TTM

-$39MNI TTM

-0.3xP/E TTM

Latest Earnings

10-K

FY FY2025Mar 24, 2026

Medicus Pharma Ltd. (MDCX), a clinical-stage biotech company, reported a net loss of $35.4M for FY 2025 ending December 31, 2025, driven by total operating expenses of $34.4M, including $17.9M in general and administrative, $7.7M in research and development, and $8.7M in in-process R&D for Teverelix. Loss from operations was $34.4M, with additional other expenses of $1.1M contributing to the...

Read full analysis View SEC Filing

What Changed Recently

Securities IssuanceMar 5, 2026

Unregistered Sales of Equity Securities. Pursuant to the previously disclosed Standby Equity Purchase Agreement (the "SEPA"), dated February 10, 2025, between M

View filing →

View all recent events →

Fundamentals

How The Business Makes Money

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer.

Industry Biotechnology

Company Profile

CIK0001997296

ISINCA58471K2020

Address300 Conshohocken State Rd. Suite 200, W. Conshohocken, 19428, CA

SEC EDGAR